BIOLINERX
BioLineRx is a clinical-stage, publicly-traded (NASDAQ/ TASE: BLRX) biopharmaceutical development company based in Jerusalem, Israel. The Company develops products suitable for the pharmaceutical market satisfying an unmet medical need or exhibiting advantages over current therapies.
BIOLINERX
Industry:
Biotechnology Medical Device Therapeutics
Founded:
2003-01-01
Address:
Jerusalem, Yerushalayim, Israel
Country:
Israel
Website Url:
http://www.biolinerx.com
Total Employee:
51+
Status:
Active
Contact:
+972 2-548-9100
Email Addresses:
[email protected]
Total Funding:
196.74 M USD
Technology used in webpage:
IPv6 YouTube COVID-19 Facebook Sharer New Relic Mobile Optimized Apple Whitelist FLoC Opt-Out FLoC Drupal
Similar Organizations
Aimmune Therapeutics
Aimmune Therapeutics is a clinical-stage biopharmaceutical company that improves the lives of people with food allergies.
Cellular Biomedicine Group
CBMG is a clinical-stage biopharmaceutical firm engaged in the development of immunotherapies for cancers and stem cell therapies.
Checkmate Pharmaceuticals
Checkmate Pharma is a clinical stage biopharmaceutical company developing a new approach for cancer immunotherapy.
Gamida Cell
Gamida Cell is an advanced cell therapy company committed to finding cures for patients with blood cancers and serious blood diseases.
Hookipa Pharma
Hookipa is a clinical stage biotech company developing best-in-class active immunization therapies for infectious diseases and oncology.
Proteostasis Therapeutics
Proteostasis Therapeutics is a clinical stage biopharmaceutical company developing small molecule therapeutics to treat cystic fibrosis.
SAB Biotherapeutics
SAB Biotherapeutics is a clinical-stage biopharmaceutical development company.
Spero Therapeutics
Spero Therapeutics develops therapeutics for treatment of gram-negative infections.
Current Advisors List
Current Employees Featured
Founder
Stock Details
Acquisitions List
| Date | Company | Article | Price |
|---|---|---|---|
| 2017-03-23 | Agalimmune | Agalimmune acquired by BiolineRx | 6 M USD |
Investors List
Biotechnology Value Fund
Biotechnology Value Fund investment in Post-IPO Equity - BiolineRx
Novartis
Novartis investment in Post-IPO Equity - BiolineRx
OrbiMed
OrbiMed investment in Post-IPO Equity - BiolineRx
Pitango Venture Capital
Pitango Venture Capital investment in Venture Round - BiolineRx
Giza Venture Capital
Giza Venture Capital investment in Venture Round - BiolineRx
Teva Pharmaceutical Industries
Teva Pharmaceutical Industries investment in Venture Round - BiolineRx
Yehuda Zisapel
Yehuda Zisapel investment in Venture Round - BiolineRx
Star Ventures
Star Ventures investment in Venture Round - BiolineRx
Key Employee Changes
| Date | New article |
|---|---|
| 2022-06-16 | BioLineRx Announces Appointment of Commercial Strategy and Operations Veteran Holly W. May as Chief Commercial Officer |
Official Site Inspections
http://www.biolinerx.com Semrush global rank: 4.95 M Semrush visits lastest month: 1.72 K
- Host name: 147.75.40.150
- IP address: 147.75.40.150
- Location: Amsterdam Netherlands
- Latitude: 52.2832
- Longitude: 4.7521
- Timezone: Europe/Amsterdam
- Postal: 1119
More informations about "BiolineRx"
BioLineRx - Wikipedia
BioLineRx is a drug development company When promising compounds are discovered, the firm leads them through preclinical trials and engages other companies to further develop them into commercializable drugs. The company entered into its first major commercialization agreement in 2009 when it partnered with Ikaria Holdings Inc. to develop its BL-1040 compound. In 2010…See details»
BioLineRx and Ayrmid Ltd. Enter into Exclusive License Agreement …
Nov 21, 2024 As part of this transaction, Ayrmid expects to transition certain members of BioLineRx's U.S.-based commercial organization, who will support both stem cell transplant …See details»
BioLineRx - The Org
BioLineRx, or BioLine, is a publicly traded drug development company that seeks to discover compounds for disease treatment and develop them into commercializable drugs. Industries. …See details»
BioLineRx | Learn About BioLineRx
BioLineRx was born from the opportunity to source innovative compounds and advance them forward to improve the way we treat diseases. While there is no shortage of excellent scientific ideas and molecules all around us, ideas that …See details»
BioLineRx | Meet Our Team
PRESIDENT, BioLineRx USA. Tsipi Keren-Lehrer, BSC, LLBHEAD OF BUSINESS DEVELOPMENT AND STRATEGIC ADVISOR, , , , , , , , Our team is growing. Join us as we expand our pipeline of potential best-in-class therapies …See details»
BiolineRx - Crunchbase Company Profile & Funding
BiolineRx may be growing as evidenced by the FDA approval of its product Aphexda, which is the first innovation in stem cell mobilization for multiple myeloma to be approved in the U.S. in a decade. This approval is a significant …See details»
BioLineRx and Ayrmid Ltd. Enter into Exclusive License Agreement …
Nov 21, 2024 BioLineRx Ltd. (NASDAQ: BLRX) (TASE: BLRX), a commercial stage biopharmaceutical company pursuing life-changing therapies in oncology and rare diseases, …See details»
BioLineRx Reports Third Quarter 2024 Financial Results and …
6 days ago Certain members of the BioLineRx U.S.-based commercial organization will be transitioned to Ayrmid Pharma Ltd. Received $9 million equity investment from certain funds …See details»
BioLineRx Company Profile - Office Locations, Competitors ... - Craft
Sep 9, 2024 BioLineRx is a biopharmaceutical company focused on oncology. It in-licenses compounds, develops them through pre-clinical and/or clinical stages, and then partners with …See details»
Press Releases - BioLineRx
BioLineRx Announces Abstract on Pilot Study Data from Phase 2 Combination Clinical Trial Evaluating Motixafortide in First-Line Pancreatic Cancer (PDAC) at American Society of …See details»
BioLineRx to Report Third Quarter 2024 Results on November 25, …
Sep 30, 2024 Management to Hold Conference Call at 8:30 a.m. EST. TEL AVIV, Israel, Nov. 20, 2024 /PRNewswire/ -- BioLineRx Ltd. (NASDAQ: BLRX) (TASE: BLRX), a commercial …See details»
BioLineRx | Partner with Us
BioLineRx welcomes partnerships and collaborators to help us further our pipeline of drugs for unmet needs in cancer and rare disease treatment. We have entered into partnerships with …See details»
BioLineRx Reports Third Quarter 2024 Financial Results and …
6 days ago BioLineRx will supply motixafortide on a cost-plus basis, for both commercial and development supply Certain members of the BioLineRx U.S.-based commercial organization …See details»
BioLineRx Accesses Second Tranche of $20 Million Under …
Apr 10, 2024 As of December 31, 2023, BioLineRx reported cash, cash equivalents, and short-term bank deposits of $43.0 million. In addition to the $20 million drawdown of the loan tranche …See details»
Earnings call: BioLineRx announces Q3 results and strategic shifts
Nov 25, 2024 BioLineRx Ltd . (NASDAQ: BLRX), a biopharmaceutical company, reported significant developments in its Q3 2024 earnings call, including a major licensing deal with …See details»
Holly May - BioLineRx
Holly May has served as President of BioLineRx USA since September 2022. From June 2022 to September 2022, Ms. May served as Chief Commercial Officer. Prior to joining BioLineRx, she …See details»
BioLineRx Reports Strategic Moves in Q3 2024 - Markets Insider
6 days ago BioLineRx Ltd. is a biopharmaceutical company focused on developing therapies for oncology and rare diseases, with its first approved product being APHEXDA® (motixafortide) …See details»
BioLineRx Reports First Quarter 2024 Financial Results and Recent ...
May 28, 2024 "In this first full quarter post APHEXDA® approval, we were pleased by the steady growth in adoption and repeat purchases by transplant centers, which is consistent with our …See details»
Discover Our Pipeline - BioLineRx
In May 2024, BioLineRx announced a clinical trial collaboration with St. Jude Children’s Research Hospital, Inc. to advance a multi-center Phase 1 clinical trial evaluating the safety, tolerability, …See details»